Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women

HIV Medicine

Volumn 12, Issue 9, 2011, Pages 570-579

  Conradie, F ^a   Zorrilla, C ^b   Josipovic, D ^a   Botes, M ^c   Osiyemi, O ^d   Vandeloise, E ^e   Eley, T ^e   Child, M ^e   Bertz, R ^e   Hu, W ^e   Wirtz, V ^e   Mcgrath, D ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c Scion Clinical Research   (South Africa)

^d Triple O Medical Services Inc   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atazanavir; HIV; Pregnancy; Prevention of mother to child transmission; Protease inhibitor

Indexed keywords

ATAZANAVIR; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GLUCOSE INTOLERANCE; HEMATOCRIT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPOCAPNIA; HYPOGLYCEMIA; INFECTION; JAUNDICE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY DISTRESS SYNDROME; RESTRICTIVE CARDIOMYOPATHY; SIDE EFFECT; THIRD TRIMESTER PREGNANCY; VOMITING;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; OLIGOPEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PUERTO RICO; PYRIDINES; RITONAVIR; SOUTH AFRICA; UNITED STATES; VIRAL LOAD;

EID: 80053383846     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00927.x     Document Type: Article

References (39)

1. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at (accessed 15 September 2009).
2. European AIDS Clinical Society. Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe Version 5-3, 2010. Available at (accessed 10 March 2010).
3. National Department of Health South Africa. National Antiretroviral Treatment Guideline, 2004. Available at (accessed 11 March 2010).
4. Anderson BL, Cu-Uvin S. Pregnancy and optimal care of HIV-infected patients. Clin Infect Dis 2009; 48: 449-455.
5. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538-539.
6. Bouillon-Pichault M, Jullien V, Azria E et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother 2009; 63: 1223-1232.
7. Mirochnick M, Best BM, Stek AM et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49: 485-491.
8. Aweeka FT, Stek A, Best BM et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2010; 11: 232-238.
9. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008; 4: 1023-1033.
10. Bongiovanni M, Cicconi P, Landonio S et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005; 26: 88-91.
11. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
12. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-718.
13. Acosta EP, Zorrilla C, Van Dyke R et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2: 460-465.
14. van Heeswijk RP, Khaliq Y, Gallicano KD et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76: 588-597.
15. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071-1087.
16. von Hentig N, Nisius G, Lennemann T et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1, 000/100mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther 2008; 13: 1039-1046.
17. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17: 1195-1199.
18. Ripamonti D, Cattaneo D, Maggiolo F et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21: 2409-2415.
19. Agarwala S, Eley T, Filoramo D et al. Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment naive HIV-infected patients. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 2006 [Abstract 85].
20. Wang X, Zhang J, Chung E et al. Effects of famotidine on the pharmacokinetics of atazanavir when given with ritonavir with or without tenofovir in HIV-infected subjects. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands, 2009 [Abstract P-30].
21. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004; Clarification August 2009. Available at (accessed 10 March 2010).
22. Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-436.
23. Bryson YJ, Mirochnick M, Stek A et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 2008; 9: 115-125.
24. Cressey TR, Van Dyke R, Jourdain G et al. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother 2009; 53: 2189-2191.
25. Mirochnick M, Dorenbaum A, Holland D et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21: 835-838.
26. Eley T, Child M, Wang Y et al. The steady state pharmacokinetics (PK) of atazanavir/ritonavir (ATV/RTV) during pregnancy in HIV+ women. 47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA, USA, 2009 [Abstract 279].
27. Waffarn F, Carlisle S, Pena I, Hodgman JE, Bonham D. Fetal exposure to maternal hyperbilirubinemia. Neonatal course and outcome. Am J Dis Child 1982; 136: 416-417.
28. Cotton DB, Brock BJ, Schifrin BS. Cirrhosis and fetal hyperbilirubinemia. Obstet Gynecol 1981; 57: 25S-27S.
29. Dubey AP, Garg A, Bhatia BD. Fetal exposure to maternal hyperbilirubinemia. Indian Pediatr 1983; 20: 527-528.
30. Lipsitz PJ, Flaxman LM, Tartow LR, Malek BK. Maternal hyperbilirubinemia and the newborn. Am J Dis Child 1973; 126: 525-527.
31. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-167.
32. American Academy of Pediatrics. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Pediatrics 1994; 94: 558-565.
33. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol 2004; 28: 326-333.
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 2011. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 31 March 2011).
35. Vincent I, Piketty C, Gerard L et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a substudy of puzzle2-ANRS 107 trial. 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 [Abstract 62].
36. Zhu L, Laio S, Child M et al. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100mg once daily compared to lopinavir/ritonavir 400/100mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. 9th International Workshop on Clinical Pharmacology of HIV Therapy, 2008 [Abstract O23].
37. Mirochnick M, Stek A, Capparelli E et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract T-140].
38. von Hentig N, Babacan E, Lennemann T et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62: 579-582.
39. McGrath D, Uy J, Yang R, Thiry A, Mancini M, Absalson J. Efficacy and safety by racial group in ARV-naive subjects treated with atazanavir/ritonavir or lopinavir/ritonavir: 48-weeks results for the CASTLE study (AI424138). XVII International AIDS Conference. Mexico City, Mexico, 2008 [Abstract TUPE 0058].